Shares of AstraZeneca Pharma India Ltd fell 1.5% on 7th August after touching a day’s high of Rs 8,807, despite the company announcing plans to launch Eculizumab — marketed as Soliris — in India this August for the treatment of rare and severe blood disorders.

Earlier in January, AstraZeneca received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Eculizumab in India. This approval allows the sale of the 300 mg infusion under the brand name Soliris.

Soliris is used to treat two rare and serious blood disorders — Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). Both conditions can damage blood cells and clog small blood vessels. Moreover, they lead to life-threatening complications.

Eculizumab is a monoclonal antibody that helps by blocking the process that causes this damage. It reduces symptoms and prevents further health risks.

At 11:44 AM, the shares of AstraZeneca were trading 1.38% lower at Rs 8,712.50 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!